With more than 10 percent of its revenues invested in research and development, Nucletron continuously seeks improvement of its existing product range and creation of new treatment options that improve patients' quality of care through curative and palliative treatment. The company's continued efforts in R&D, both in-house and through partnerships with leading academic institutions, have resulted in a strong and unique IP base.
Headquartered in The Netherlands, Nucletron delivers customized solutions to more than 3,000 institutions in more than 120 countries, equating to global sales of euro 120 million ($160 million), with operating profit levels that rank in the upper quartile of the industry. Worldwide, Nucletron has offices in 16 countries, including a production and R&D facility in The Netherlands, R&D centers in Uppsala, Sweden and Oslo, Norway and sales, marketing, service and support operations in Europe, Asia, Australia and North America.
The supervisory board of Nucletron will be chaired by Rob Westerhof, who has held senior positions in Asia and in the USA for Philips Medical Systems and Philips Electronics. Commenting on the spin-off, Westerhof stated, "I am excited to join Nucletron's supervisory board. Being involved in the medical business for more than 15 years in various positions throughout the world, I trust that I can make a contribution. Nucletron represents a strong brand in the world of oncology and related areas, and there are excellent opportunities for expanding our market share. I am looking forward to working with the new management team and further strengthening Nucletron."
Nucletron is a knowledge-based leader in Radiation Oncology, working
with clinical teams to realize innovative solutio
Copyright©2007 PR Newswire.
All rights reserved